Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients - Wikidata - wikimedia - TriplyDB

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients

http://www.wikidata.org/entity/Q34566472

about

ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it Identification of a recurrent STRN/ALK fusion in thyroid carcinomas A consensus statement on the gender perspective in lung cancer.Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis.Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement.ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.Combination of conventional immunohistochemistry and qRT-PCR to detect ALK rearrangement.Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: A Proposal of the Korean Cardiopulmonary Pathology Study Group.Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis.ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Alectinib for ALK-positive non-small-cell lung cancer.Lung Cancer Biomarkers.New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer.ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.Immunohistochemistry for predictive biomarkers in non-small cell lung cancer.Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.Screening for ALK abnormalities in central nervous system metastases of non-small-cell lung cancer.ALK protein expression in pulmonary adenocarcinoma of Tunisian patients.[Diagnosis for ALK positive non-small cell lung cancer].Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients.Detection of ALK expression in non-small-cell lung cancer with ALK gene rearrangements--comparison of multiple immunohistochemical methods.[New development lines in immunology. Perspective of pathology].ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients Discrepancies between ALK protein disruption and occurrence of gene rearrangement in Polish NSCLC patients

P2860

Q28083386-EE4C358C-5E05-48EA-8540-E597ED9CF032 Q28539208-A8C57C43-A926-431D-A4A4-D8694545871B Q30240700-6F7720E7-9E7F-4729-9DD3-F3B80F4693C6 Q31167585-C3480895-6FD4-4CBD-8BB1-0CB6F0E79016 Q34231928-B17F8706-EB5F-41D7-8464-F8C32B56FEE5 Q34388696-C6FBAFFC-B8CE-4D30-B55A-CB2DF15F4600 Q35200526-288FCF77-B9BD-4643-91F6-3F2DA647B877 Q35256603-72C0D5F0-064F-442E-BE18-31359AF0FFE4 Q36866859-EE6E8567-0325-455F-A989-62E17E9BEB05 Q37416902-82324216-7157-4CC0-B3F0-0076DFDB6484 Q37583862-6135424F-F9BF-4672-A04B-73B0CB02EBBB Q37631021-DC215170-1F80-4EBF-A17F-70F9415940C4 Q37688499-646014AE-D5BD-4B3D-A52B-5C2FAD24E562 Q37696243-4B3F9FD5-9E3B-4C73-8412-FA4F5ACE8E1D Q38148969-4840C359-6F3D-47FE-9C78-72995A6E0786 Q38584814-29828383-E6B9-4C13-8565-ADBD95AF36D0 Q38846027-59D37A7B-1DB4-4F6A-8CD4-CB49F159ADBD Q39027394-E9D6DC57-B189-45B5-8F5F-A03DB5F0EEAC Q39139889-53A04C88-AB7C-443F-88C1-C470732E6D8E Q40084048-2342789A-7FEF-41E2-AB95-BD942A6FCFD0 Q40523842-6BFA0A2A-7C07-4C07-8EAB-598DDE943B7E Q46624082-1A65ADFA-0739-4176-90EC-0F94EAB1E484 Q47140225-45CF39A2-D763-4E39-8605-31F58408960A Q47578326-23052A69-70C7-4286-8C99-E235058E9B6C Q48419474-095591BE-A978-4737-9027-C3473E768487 Q51049573-12E9EE70-39DB-469C-B69A-63B289E0E074 Q53223727-F9D72E3F-1ED4-4293-9C8D-62786A8F1EA8 Q54272495-2DEE9FB2-6768-49AA-857C-1AC67429C057 Q54369379-801CE669-3634-45A6-8ED6-50A553B517E8 Q54397306-BC324DEE-1FED-4939-AA8D-EF193BC71968 Q57074582-914413BF-49C1-49E4-906E-00BD7C4BABCD Q58804485-DD22079D-1366-4016-9AED-D0B34E19D847

P2860

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients

http://www.wikidata.org/entity/Q34566472

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@ast

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@en

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@nl

type

label

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@ast

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@en

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@nl

prefLabel

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@ast

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@en

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@nl

P1433

Q34566472-01CF3095-7CB0-4D03-9A1D-A461A2393CB4

P1476

Q34566472-CC6F1D45-6C12-4BC2-85B8-BCFBC5956E5E

P2093

Q34566472-101AAC32-F87D-40F3-8675-67567CC722BC

Q34566472-1A67075E-8669-442C-AE3A-07673B27CA2B

Q34566472-1F54788B-4BE6-4B0E-88EE-0EFB81987D75

Q34566472-2BA7FE38-28F0-43A6-A9B6-72B2E2DCAD0D

Q34566472-534A2DAB-1583-4788-BEFF-2093BC608C44

Q34566472-81BC587D-D2E0-48CF-AB25-32058938AFDD

Q34566472-B0AAE434-22E8-4D84-8C1E-39FF4CE1AB39

Q34566472-CE79DAE8-1D72-4029-B7E5-13963DFD02C8

Q34566472-D38D7C18-8FA5-4E94-87ED-5DD79E5A0E96

P2860

Q34566472-024742EA-EEDE-4727-B9B2-C7E270AEC80D

Q34566472-1349A220-29EB-4D38-8F28-89DC32938BCB

Q34566472-414AA2AE-0B22-4926-9761-7E89718970F1

Q34566472-48415AF6-255B-4291-A3D8-7419B8173E97

Q34566472-4BBF9690-4833-457E-8FE4-789F8E2AF309

Q34566472-4D51688A-CA6A-4FF8-B7B3-93413F02717F

Q34566472-583C996D-D8B6-4980-942C-A26B844BD43F

Q34566472-59B40570-93E7-40DD-96BA-E4AF374A19B5

Q34566472-5CB555D6-BCB0-4134-89C0-00AAE7C13932

Q34566472-8D21D336-BA2C-4CA8-91C4-B8FDD8CD676E

P304

Q34566472-5D76E32A-1F18-4146-A66E-63302E4A43D5

P31

Q34566472-A2DE7B2E-887F-4529-A3CE-2FA82F0B5EFE

P356

Q34566472-B364D720-E5BD-4DFC-A92D-8AC925BA536B

P407

Q34566472-930EE6D1-EAEA-41C8-BAA3-D48315E6D6C1

P433

Q34566472-826B5213-9D45-48A6-9F87-0E2A686B515E

P478

Q34566472-4992B76D-9F76-40A4-B7FD-C56E7E2B2605

P50

Q34566472-3DA6BA1E-C256-4666-8558-F2696590D2A7

Q34566472-69BBFC5B-6167-4B9E-97B4-6DFA5C978AA8

Q34566472-A14D7042-002E-4E30-91DD-E0D165873CD9

Q34566472-DD20A9C2-B8C4-458A-BCBB-DF93DED96F62

P577

Q34566472-60A3F539-8599-479E-8DA4-FB8BF08FB605

P5875

Q34566472-9A8F87C2-4C3A-4240-A7B3-179C5F2B7A3E

P698

Q34566472-E42F51BF-0C68-4189-BE37-D4E7D4D9E036

P921

Q34566472-9DF246EA-893C-4135-B3B1-DA0FA818E712

P932

Q34566472-9E634544-5E7E-40CB-8400-22D23E52E5B6

P356

JOURNAL.PONE.0052261

P1433

P1476

Fluorescence in situ hybridiza ...... mall cell lung cancer patients

@en

P2093

Alejandro Navarro-Mendivill

http://www.w3.org/2001/XMLSchema#string

Alex Martinez-Marti

http://www.w3.org/2001/XMLSchema#string

Ma Ángeles Montero

http://www.w3.org/2001/XMLSchema#string

Mercedes Canela

http://www.w3.org/2001/XMLSchema#string

Natalia Tallada

http://www.w3.org/2001/XMLSchema#string

Nuria Murtra-Garrell

http://www.w3.org/2001/XMLSchema#string

Pablo Martinez

http://www.w3.org/2001/XMLSchema#string

Susana Cedrés

http://www.w3.org/2001/XMLSchema#string

Victor Rodriguez-Freixinos

http://www.w3.org/2001/XMLSchema#string

P2860

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

P304

e52261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0052261

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Josep Castellvi

Santiago Ramon y Cajal

Enriqueta Felip

Javier Hernandez-Losa

P577

2013-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235381212

http://www.w3.org/2001/XMLSchema#string

P698

23359795

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

3554741

http://www.w3.org/2001/XMLSchema#string